preprint
The menace of antimicrobial resistance to public health is constantly arising globally. Many pathogenic bacteria use mechanisms such as mutations and biofilm formation, significantly reducing antimicrobial agents' efficacy. In this cross-sectional study, we aimed to determine the prevalence of selected extended spectrum β-lactamase (ESβLs) genes and analyse the biofilm formation abilities of the isolated bacteria causing urinary tract infection among adult patients against selected drug dosages seeking Medicare at Kiambu Level 5 Hospital, Kenya. The double-disk synergy test was used for phenotypic identification of ESβLs producing isolates, while microtiter plate assays with some modifications were used for the biofilm formation test. A total of 10 isolates were bioassayed for ESβL genes presence out of 57 bacteria isolates obtained from urine samples. This study found the blaTEM genes to be the most prevalent ESβLs type 10/10 (100%), followed by blaOXA and blaSHV genes at 4/10 (40%) and 3/10 (30%), respectively. In addition, the co-carriage of blaTEM and blaSHV was 50% lower than that of blaTEM + blaOXA genes at 66.7% among the study Escherichia coli isolates. Biofilm formation was positive in 36/57 (63.2%) of the isolates tested, with most being Gram-negative 25/36 (69.4%). Escherichia coli 15/36 (41.7 %), Klebsiella species 7/36 (19.4%), and Staphylococcus aureus 7/36 (19.4%) were the dominant biofilm formers. However, there was no significant difference in biofilm formation among all tested isolates, with all isolates recording p-values above 0.05. In light of these findings, biofilm formation potential coupled with antimicrobial resistance genes in UTI isolates could likely lead to difficult to treat infections.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1099/acmi.0.000632.v3
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.